Applied Therapeutics, Inc. financial data

Symbol
APLT on Nasdaq
Industry
Pharmaceutical Preparations
Location
545 Fifth Avenue, Suite 1400, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 141 % +55.8%
Debt-to-equity 243 %
Return On Equity -583 % -123%
Return On Assets -170 % +30.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 116M shares +50.7%
Common Stock, Shares, Outstanding 116M shares +50.9%
Entity Public Float 63.9M USD +130%
Common Stock, Value, Issued 11K USD +57.1%
Weighted Average Number of Shares Outstanding, Basic 144M shares +59.2%
Weighted Average Number of Shares Outstanding, Diluted 144M shares +59.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 122K USD
Research and Development Expense 52.4M USD +3.27%
General and Administrative Expense 39.7M USD +76.8%
Operating Income (Loss) -92.3M USD -47.6%
Nonoperating Income (Expense) -95M USD -179%
Net Income (Loss) Attributable to Parent -187M USD -94.1%
Earnings Per Share, Basic -1.53 USD/shares -59.4%
Earnings Per Share, Diluted -1.68 USD/shares -75%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 98.9M USD +164%
Cash, Cash Equivalents, and Short-term Investments 22.9M USD -58.9%
Other Assets, Current 366K USD -56.3%
Assets, Current 105M USD +135%
Operating Lease, Right-of-Use Asset 1.96M USD +285%
Assets 107M USD +136%
Accounts Payable, Current 2.84M USD -52.8%
Contract with Customer, Liability, Current 212K USD
Liabilities, Current 99M USD +78.3%
Operating Lease, Liability, Noncurrent 1.71M USD +3780%
Liabilities 101M USD +79%
Accumulated Other Comprehensive Income (Loss), Net of Tax 51K USD
Retained Earnings (Accumulated Deficit) -618M USD -43.5%
Stockholders' Equity Attributable to Parent 5.89M USD
Liabilities and Equity 107M USD +136%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.9M USD -171%
Net Cash Provided by (Used in) Financing Activities 115M USD
Net Cash Provided by (Used in) Investing Activities 13.9M USD +45.6%
Common Stock, Shares Authorized 250M shares +25%
Common Stock, Shares, Issued 116M shares +50.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 96.6M USD +1443%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 98.9M USD +164%
Deferred Tax Assets, Valuation Allowance 151M USD +12.7%
Deferred Tax Assets, Gross 151M USD +12.6%
Operating Lease, Liability 1.97M USD +268%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -187M USD -94%
Lessee, Operating Lease, Liability, to be Paid 2.83M USD +413%
Operating Lease, Liability, Current 264K USD -46.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 556K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 546K USD +28.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +176%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 858K USD +4947%
Lessee, Operating Lease, Liability, to be Paid, Year Three 550K USD
Deferred Tax Assets, Operating Loss Carryforwards 94.1M USD +6.84%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 563K USD
Additional Paid in Capital 624M USD +48.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 139K USD -48.9%
Share-based Payment Arrangement, Expense 7.99M USD -2.29%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%